LabCorp Updates 2013 Guidance, Provides Preliminary Guidance for 2014 | GenomeWeb

NEW YORK (GenomeWeb News) – Laboratory Corporation of America after the close of the market on Tuesday reaffirmed its revenue guidance for full-year 2013 and trimmed the low end of its adjusted EPS.

The company also provided preliminary guidance for full-year 2014.

Revenues for 2013 were reaffirmed at a growth rate of 3 percent, while adjusted EPS was changed to a range of $6.90 to $7.05 from a prior range of $6.95 to $7.05.

For full-year 2014, LabCorp gave preliminary guidance of 2 percent revenue growth and $6.50 in non-GAAP EPS, excluding amortization.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.